Reimagining Early-Phase Clinical Development in Japan: From Regulatory Obligation to Global Acceleration

Area of Science:

• Clinical Pharmacology
• Drug Development
• Regulatory Science

Background:

• Japan historically faced "Drug Lag" and "Drug Loss" due to mandatory Phase I studies.
• Recent regulatory reforms offer new opportunities for Japan in global drug development.

Purpose of the Study:

• To redefine the value of Japanese Phase I studies in early drug development.
• To evaluate three strategic options: Phase I waiver, first-in-human studies in Japan, and multifunctional Phase I studies.

Main Methods:

• Analysis of 12 internal Japanese Phase I waiver consultations.
• Nationwide survey of early phase clinical trial sites in Japan.

Main Results:

• Japan possesses a robust early-phase clinical trial infrastructure with extensive experience.
• Japanese sites demonstrate capability for specialized evaluations and diverse patient enrollment.
• Clinical trial initiation in Japan is globally competitive, often faster than in the EU.

Conclusions:

• Japan is well-positioned for first-in-human and early phase trials, accelerating global drug development.
• A flexible, case-by-case approach leveraging Japan's capabilities is proposed.
• Integrating Japan into early development enhances the drug-discovery ecosystem and patient access.